Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$15.62M |
$1.25
+11.06%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$15.47M |
$0.52
|
|
UEEC
United Health Products, Inc.
CelluSTAT is a surgical hemostatic device used in operative settings, categorizing the company as a Surgical Equipment manufacturer.
|
$15.46M |
$0.06
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$15.45M |
$1.04
-7.96%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$15.35M |
$0.74
+1.39%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$15.00M |
$0.29
-7.98%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$14.68M |
$1.84
+2.50%
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$14.66M |
$0.68
-17.27%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$14.41M |
$1.41
+15.16%
|
|
CODX
Co-Diagnostics, Inc.
Co-Dx PCR Pro instrument is a diagnostic equipment product directly manufactured by the company.
|
$14.38M |
$0.38
+17.54%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$14.25M |
$3.20
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$13.82M |
$0.41
|
|
AMS
American Shared Hospital Services
AMS is directly operating outpatient radiation therapy centers (Direct Patient Services) in Rhode Island, Puebla, and other locations.
|
$13.74M |
$2.14
-1.38%
|
|
PFHO
Pacific Health Care Organization, Inc.
PFHO provides workers' compensation cost containment services, including healthcare provider network access and case management, within the healthcare services ecosystem.
|
$13.70M |
$1.08
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.68M |
$0.07
|
|
CFOO
China Foods Holdings Ltd.
The company provides customized wellness consultation programs and related services.
|
$13.45M |
$0.66
|
|
MRM
MEDIROM Healthcare Technologies Inc.
MOTHER Bracelet and related biometric sensing capabilities align with Medical Devices & Biometrics.
|
$13.37M |
$2.00
+1.27%
|
|
ACUT
Accustem Sciences Inc.
Company plans to offer Laboratory Testing & Advisory Services leveraging existing lab infrastructure and additional sequencing/heritage panels.
|
$13.27M |
$0.88
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$13.15M |
$4.16
-0.12%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$13.15M |
$0.47
+0.41%
|
|
YMAT
J-Star Holding Co., Ltd. Ordinary Shares
Produces medical device components used in healthcare applications, reflecting a direct product line.
|
$13.10M |
N/A
|
|
ADGM
Adagio Medical Holdings, Inc.
ADGM is a medical technology company whose core offerings are medical devices/biometrics for cardiac ablation.
|
$12.92M |
$0.86
+1.59%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$12.66M |
$0.25
+5.12%
|
|
ALUR
Allurion Technologies Inc.
Allurion Balloon is a swallowable medical device used for weight management.
|
$12.50M |
$1.62
+12.50%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$12.01M |
$1.72
+2.38%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$11.87M |
$2.58
+2.79%
|
|
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
MEDIFLY maggot debridement therapy is Cuprina's flagship wound care device/product.
|
$11.74M |
$0.65
-2.13%
|
|
EKSO
Ekso Bionics Holdings, Inc.
Product portfolio includes Ekso Indego Personal and EksoNR, both medical devices used for rehabilitation and mobility assistance.
|
$11.67M |
$4.48
+2.28%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$11.40M |
$0.27
+2.28%
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$11.27M |
$1.08
-1.82%
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$11.01M |
$3.42
+11.56%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$10.92M |
$1.45
+7.41%
|
|
SINT
Sintx Technologies, Inc.
Core business is manufacturing medical-grade silicon nitride materials used in medical devices, aligning with Medical Devices & Biometrics.
|
$10.72M |
$3.91
+7.12%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's TMAb platform and immuno-oncology focus places it within Immunology Therapeutics.
|
$10.66M |
$8.75
+1.74%
|
Showing page 33 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
